Founded Year
2018Stage
Seed VC | AliveTotal Raised
$2.54MLast Raised
$2.2M | 5 mos agoAbout Rhaeos
Rhaeos was founded in 2018 to address a critical unmet need in the care of patients with hydrocephalus. Arising from a collaboration between materials scientists and neurological surgeons at Northwestern University, the company has developed a noninvasive thermal sensor for use in the monitoring of ventricular shunt function.
Rhaeos Headquarter Location
2123 Dewey Ave
Evanston, Illinois, 60201,
United States
Expert Collections containing Rhaeos
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Rhaeos is included in 4 Expert Collections, including Medical Devices.
Medical Devices
8,279 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Digital Health
12,800 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health Monitoring & Diagnostics
462 items
Companies developing wearable health monitoring solutions (human health only). Companies tagged as #Wearables (*note: this tag may also apply to companies outside the scope of this collection)
Health IT
7,900 items
Latest Rhaeos News
Apr 9, 2022
Private medical device company Rhaeos , which is focused on the care of patients with chronic medical conditions, announced the issuance of U.S. patents that cover flexible, wearable sensors for non-invasive monitoring of subdermal fluid flow. These patents include wearable sensors that address cerebrospinal fluid in hydrocephalus shunts and blood flow in both capillaries and large vessels. Biological fluid flow is a key diagnostic and therapeutic biomarker for numerous chronic medical conditions including hydrocephalus, where cerebrospinal fluid flow in implanted ventriculoperitoneal shunts is of critical importance. However, quantified analysis of biological fluid flow is often frustrated by the need for invasive fluid access, the use of bulky wired electronics that tether the patient, and motion artifacts in skin-mounted probes. Rhaeos’ novel Epidermal Thermal Flow Sensor technology is designed to overcome these limitations by enabling a small, wireless, flexible device that gently adheres to the skin like a soft bandage. Novel mechanical and thermal engineering approaches result in a sensor that can measure flow-induced temperature responses on skin with a precision of one hundredth of a degree. These improvements, combined with advanced analytics, enable reliable flow measurements with incredible precision down to a few microliters per minute. “The challenge in biological flow sensing is getting useful signals without physically contacting the fluid and without immobilizing the patient,” says R. Chad Webb, PhD, chief technical officer. “This technology overcomes both challenges by mechanically matching the sensor to the skin surface, eliminating motion-induced measurement noise and enabling reliable detection of the subtle flow-induced thermal responses”. The technology has been demonstrated in multiple pilot studies showing effectiveness across a range of healthcare applications, with peer-reviewed publications in Nature and Science family journals, among others. The technology is also a key enabler of FlowSense, a Rhaeos product currently being used in a pivotal clinical trial for monitoring cerebrospinal fluid flow in hydrocephalus shunts. “The ability to noninvasively measure flow through biological systems is broadly useful for a number of medical applications,” says Siddharth R. Krishnan, PhD, Rhaeos Co-Founder. “We’re very excited about the potential to improve care for patients with hydrocephalus, where the measurement of cerebrospinal fluid flow through implanted shunt systems could allow us to identify aberrant patterns and malfunctions more efficiently.” U.S. Patent No. 11,160,458, “Epidermal Devices for Analysis of Temperature and Thermal Transport Characteristics”, describes sensor designs and analytical methods for thermal analysis of tissue, including noninvasively monitoring fluids such as blood flow. Meanwhile, U.S. Patent No. 11,259,754, “Wireless and Noninvasive Epidermal Electronics,” describes conformable devices to measure subdermal fluid flow and related methods. These novel devices and methods enable the detection of thermal flow signals by employing key materials, geometries, and signal processing techniques. Rhaeos, Inc. has exclusive worldwide rights to commercialize these inventions as part of a broad intellectual property portfolio generated internally and licensed from Northwestern University and the University of Illinois. Share:
Rhaeos Web Traffic
Rhaeos Rank
When was Rhaeos founded?
Rhaeos was founded in 2018.
Where is Rhaeos's headquarters?
Rhaeos's headquarters is located at 2123 Dewey Ave, Evanston.
What is Rhaeos's latest funding round?
Rhaeos's latest funding round is Seed VC.
How much did Rhaeos raise?
Rhaeos raised a total of $2.54M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.